Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong prescription growth for key products like AUVELITY and SUNOSI, successful launch of SYMBRAVO, and promising pipeline developments. The Q&A reveals positive analyst sentiment towards growth drivers and market opportunities, despite some unclear management responses. The strategic plan indicates expansion and potential new approvals, suggesting future growth. The market cap of $3.8 billion suggests moderate sensitivity to news. Overall, the combination of strong current performance and optimistic future guidance justifies a positive stock price outlook over the next two weeks.
Key Financial Performance
Total revenue (Q4 2025) $196 million, a 65% year-over-year increase, driven by robust AUVELITY growth, continued solid performance of SUNOSI, and initial contributions from SYMBRAVO.
Total revenue (Full Year 2025) $639 million, a 66% year-over-year increase, attributed to the same factors as Q4.
AUVELITY net product sales (Q4 2025) $155.1 million, a 68% year-over-year increase, reflecting strong market uptake and prescriber growth.
AUVELITY net product sales (Full Year 2025) $507.1 million, a 74% year-over-year increase, surpassing $0.5 billion in its third full year of launch.
SUNOSI net product revenue (Q4 2025) $36.7 million, a 40% year-over-year increase, driven by strong market performance.
SUNOSI net product revenue (Full Year 2025) $124.8 million, a 32% year-over-year increase, reflecting continued solid performance.
SYMBRAVO net sales (Q4 2025) $4.1 million, reflecting its second full quarter of launch.
SYMBRAVO net sales (Full Year 2025) $6.6 million, reflecting its initial contributions post-launch.
Total cost of revenue (Q4 2025) $12.3 million, compared to $10.5 million in Q4 2024, reflecting increased product sales.
Total cost of revenue (Full Year 2025) $47.5 million, compared to $33.3 million in 2024, reflecting increased product sales.
Research and development expenses (Q4 2025) $48.8 million, compared to $55 million in Q4 2024, primarily due to the completion of clinical trials for AXS-05 and solriamfetol.
Research and development expenses (Full Year 2025) $183.3 million, compared to $187.1 million in 2024, with a decrease driven by the same factors as Q4.
Selling, general and administrative expenses (Q4 2025) $169.3 million, compared to $113.3 million in Q4 2024, a 39% increase driven by commercialization activities for AUVELITY and SYMBRAVO.
Selling, general and administrative expenses (Full Year 2025) $570.6 million, compared to $411.4 million in 2024, reflecting the same drivers as Q4.
Net loss (Q4 2025) $28.6 million, compared to $74.9 million in Q4 2024, with the current quarter including $22.7 million in stock-based compensation expense.
Net loss (Full Year 2025) $183.2 million, compared to $287.2 million in 2024, with the current year including $93.8 million in stock-based compensation expense.
Cash and cash equivalents (End of 2025) $323 million, compared to $315 million at the end of 2024, indicating a stable cash position.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AUVELITY: Achieved sales of over $0.5 billion in its third full year of launch. Priority review designation for sNDA in Alzheimer's disease agitation with a PDUFA action date of April 30. Launch readiness activities underway. Prescriptions grew 42% year-over-year, with 225,000 prescriptions written in Q4. Expanded sales force to 600 representatives.
SUNOSI: Growth accelerated with net product revenue of $36.7 million in Q4, a 40% increase year-over-year. Total revenue for 2025 was $124.8 million, a 32% increase. Prescriptions grew 11% year-over-year with 54,000 prescriptions in Q4.
SYMBRAVO: Launched as a third growth pillar, generating $6.6 million in revenue for 2025. Prescriptions reached 13,000 in Q4. Coverage expanded to 52% of lives.
Market Access for AUVELITY: Commercial coverage increased from 75% to 78%, with total coverage at 86% of all lives across channels.
Market Access for SYMBRAVO: Coverage expanded to 52% of lives, with 49% in commercial and 57% in government channels.
Commercial Platform: Built a technologically enabled scalable commercial platform to support product momentum and future launches.
Sales Force Expansion: Expanded AUVELITY sales force to 600 representatives to support growing demand and potential Alzheimer's indication launch.
Pipeline Expansion: Advancing a CNS pipeline with 5 novel product candidates across 9 high-impact indications. Initiated Phase III trials for solriamfetol in ADHD and MDD, and Phase III trial for AXS-14 in fibromyalgia. Acquired AZD7325 for epilepsy treatment.
Label Expansion: Pursuing label expansion for AUVELITY in Alzheimer's disease agitation and solriamfetol in multiple new indications including ADHD, binge eating disorder, and shift work disorder.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is awaiting FDA approval for AUVELITY in Alzheimer's disease agitation, with a PDUFA action date of April 30. Regulatory delays or non-approval could impact the launch and revenue potential.
Pipeline Development Risks: The company is advancing multiple clinical trials, including Phase III trials for solriamfetol in ADHD and binge eating disorder, as well as AXS-14 in fibromyalgia. Delays, failures, or unexpected results in these trials could hinder product development and commercialization.
Market Access and Pricing Challenges: Gross-to-net discounts for AUVELITY and SUNOSI are expected to increase to the mid-50% range, and SYMBRAVO's discounts remain elevated in the high 70% range during its launch phase. These pricing pressures could impact profitability.
Commercialization Risks: The company is expanding its sales force for AUVELITY and launching SYMBRAVO, which requires significant investment. Failure to achieve expected market penetration or adoption could affect financial performance.
Supply Chain and Operational Risks: The company is scaling its commercial platform to support product launches and pipeline growth. Any disruptions in supply chain or operational inefficiencies could impact product availability and sales.
Financial Risks: The company reported a net loss of $183.2 million for 2025, despite revenue growth. Continued losses could strain financial resources, especially if cash flow positivity is delayed.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
AUVELITY in Alzheimer's disease agitation: The sNDA for AUVELITY in Alzheimer's disease agitation has been accepted with a priority review designation and a PDUFA action date of April 30. Launch readiness activities are underway, and awareness is expected to build in the quarters ahead.
AXS-05 in smoking cessation: A Phase II/III trial of AXS-05 in smoking cessation is planned, with initiation anticipated in the second quarter.
AXS-12 in narcolepsy: Following positive FDA pre-NDA meeting minutes, the R&D package is progressing, and submission is expected imminently.
Solriamfetol in multiple indications: Development is advancing for solriamfetol in ADHD, binge eating disorder, MDD with symptoms of excessive daytime sleepiness, and shift work disorder. Phase III trials for ADHD in pediatric patients are planned for the first half of the year. A Phase III trial for MDD with symptoms of excessive daytime sleepiness is set to begin this quarter. The ENGAGE Phase III trial for binge eating disorder is expected to deliver top-line results in the second half of the year. Top-line results for shift work disorder are anticipated in 2027.
AXS-14 in fibromyalgia: The FORWARD study, a Phase III trial, has been initiated to supplement previous positive Phase II and Phase III trials.
AXS-17 for epilepsy: Phase II trial-enabling activities are underway for AXS-17, a novel compound for epilepsy treatment, with updates expected in the coming months.
AUVELITY sales force expansion: The AUVELITY sales force is being expanded to approximately 600 representatives, with completion expected in the second quarter, in anticipation of increased demand and potential new indications.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the implications of the new FDA publication on the one trial policy for your trials, particularly for binge eating, shift work disorder, and ADHD?
A:The team is assessing the new FDA publication. For shift work disorder, there is alignment with the FDA that the existing clinical package could serve as supportive evidence if the current study is positive. For ADHD, the FDA requires data from both pediatric subsets (children under 12 and adolescents), which is why two concurrent studies are being conducted. This will not impact the filing timeline.
Q:Can you provide details on AXS-17, its development plan for epilepsy, and the data available?
A:AXS-17 has been studied in generalized anxiety disorder, providing safety data from chronic dosing. Preclinical studies in epilepsy models show promise, and the team is preparing for Phase II readiness. More details on the specific epilepsy indication will be provided later in the year.
Q:How will AUVELITY payer coverage evolve with the addition of the ADA label?
A:Existing coverage for MDD should generally apply to ADA. However, ADA is largely a Medicare business, so efforts are focused on ensuring sufficient Medicare Part D coverage. The team is also working to achieve 100% access and remove utilization management barriers.
Q:What is the expected launch cadence for Alzheimer's agitation, and how will gross-to-net for AUVELITY trend over time?
A:The team is preparing for a commercial launch post-approval. Gross-to-net for ADA is expected to be more favorable due to the Medicare Part D channel, which has no co-pay card utilization.
Q:What drove the double-digit year-over-year growth for SUNOSI?
A:Growth was driven by new patient starts, total active writers, and total prescriptions. Approximately 70% of prescriptions are for EDS and OSA, and 30% for EDS and narcolepsy. Growth is seen across prescriber segments, including PCPs, pulmonologists, sleep specialists, and neurologists.
Q:What is the progress of the DTC campaign for AUVELITY, and where is growth coming from?
A:The national TV campaign launched in late 2025 generated an inflection in new patient starts. Growth is coming from both primary care and psychiatry practices, with primary care being the fastest-growing segment in Q4.
Q:What is the expected reimbursement and market access for AUVELITY at steady state?
A:The goal is to secure access for as many patients as possible. Steady progress has been made in increasing covered lives, and efforts will continue for both MDD and ADA indications.
Q:What are the broader development plans for AXS-17 beyond epilepsy?
A:The focus is currently on epilepsy, but other potential indications will be explored in the future. The team is staying focused on the initial indication based on promising preclinical work.
Q:What led to the sales force expansion, and how does it align with SG&A expectations?
A:The expansion is to accelerate growth in MDD and prepare for a potential ADA indication. The larger sales force will increase reach and frequency to high-value HCPs. Despite the expansion, operating leverage is expected to continue into 2026.
Q:How is SYMBRAVO coverage evolving, and what is the impact on gross-to-net?
A:The team is negotiating with payers and PBMs to increase SYMBRAVO coverage. Gross-to-net is expected to remain elevated during the launch phase but will improve as more contracts come online.
Q:What is the timeline for the Alzheimer's agitation launch, and how will metrics be reported?
A:The team will be ready to launch within a quarter post-approval. Metrics such as the percentage of scripts from the ADA space will be shared, but typical data sources do not break out by indication.
Q:How does AXS-12 differentiate in narcolepsy, and what is the market opportunity?
A:AXS-12 offers a novel mechanism with strong data on cataplexy relief and a favorable safety profile. Narcolepsy patients often use polypharmacy, and AXS-12 is expected to be a compelling option. The orexin agonists are also expected to coexist in the market.
Q:What is the therapeutic window for AXS-17 in epilepsy, and how is dosing being optimized?
A:The team is exploring dosing to achieve the best risk-benefit profile. Initial trials in epilepsy patients will provide more information, and the mechanism of action shows promise.
Q:How does AUVELITY's safety profile compare to Rexulti for ADA, and what are its advantages?
A:The safety profile will be described in the label if approved. AUVELITY's advantages include rapid onset of action, durability of response, low side effects, and suitability as a monotherapy for MDD.
Q:What is the breakdown of Alzheimer's agitation prescriptions between community and long-term care settings?
A:Approximately 60% of prescriptions are in community-based settings and 40% in long-term care facilities. The team is preparing to address both segments.
Q:What is the gross-to-net dynamic for ADA compared to MDD?
A:Gross-to-net for ADA is expected to be more favorable due to the Medicare Part D channel, which has a more favorable profile than the commercial channel.
Q:What is the penetration of AUVELITY in the PCP segment compared to psychiatry?
A:Currently, 1/3 of the writer base is in primary care and 2/3 in psychiatry. Primary care is the fastest-growing segment, and efforts are ongoing to expand penetration.
Q:How does AXS-12 compare to orexin-based products in narcolepsy?
A:AXS-12 targets norepinephrine, similar to the pathway affected by orexin agonists. It offers benefits in cataplexy, excessive daytime sleepiness, and cognition, with a favorable safety profile. Polypharmacy is expected to continue in the market.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or lacked clarity on several questions, including: 1) Specific details on the Alzheimer's agitation launch metrics and how they will be reported. 2) Broader development plans for AXS-17 beyond epilepsy, as the response was vague about future indications. 3) The expected steady-state covered lives percentage for AUVELITY, as no specific guidance was provided. 4) The differentiation of AXS-12 in narcolepsy compared to orexin-based products, as the response lacked detailed comparisons. 5) The therapeutic window for AXS-17 in epilepsy, as the response was general and did not provide specific data or insights.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADHD Type
ADHD binge
AUVELITY Alzheimer
AUVELITY SUNOSI
AUVELITY date
AUVELITY potential
AUVELITY prescription
AUVELITY sale
AUVELITY treatment
AXS FORWARD
Axsome
Full Conference
PDUFA
Phase II
QA
SUNOSI discount
SYMBRAVO SUNOSI
compensation expense
confidence
designation
expansion AUVELITY
increase SUNOSI
initiation
launch SYMBRAVO
loss stock
medicine outcome
model
onset action
period
prescriber base
prescriber segment
prescription comparison
receipt
safety
sale launch
study Phase
trial AXS
trial solriamfetol
AXSM Transcript
Axsome Therapeutics, Inc. (AXSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
Positive5-4
The earnings call summary presents a strong financial performance with a 45% revenue increase and a reduced net loss. Additionally, there is a strategic expansion of the AUVELITY sales force and ongoing development in multiple therapeutic areas. Although some risks are noted in forward-looking statements, the overall sentiment is positive due to strong revenue growth and effective cost management. The market cap indicates a moderate reaction, likely leading to a stock price increase of 2% to 8%.
Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript
Neutral3-13
AXSM Slides
Axsome Q1 2026 slides: 57% revenue growth amid FDA approval milestone2026-05-04
Axsome Q4 2025 slides: revenue surges 66%, stock dips on expenses2026-02-23
Axsome Therapeutics Q3 2025 slides: Strong revenue growth amid pipeline expansion2025-11-03
Axsome Q2 2025 slides: revenue surges 72% YoY, pipeline advances on track2025-08-04
AXSM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
